Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia

Annals of Neurology

Volumn 53, Issue 6, 2003, Pages 693-702

  Calabresi, Paolo ^a,b   Cupini, Letizia M ^a,b   Centonze, Diego ^a,b   Pisani, Francesco ^c   Bernardi, Giorgio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; EXCITATORY AMINO ACID RECEPTOR; FELBAMATE; FOSPHENYTOIN SODIUM; LAMOTRIGINE; PHENYTOIN; REMACEMIDE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GABAERGIC TRANSMISSION; NERVE EXCITABILITY; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SODIUM TRANSPORT; STROKE; SYNAPTIC TRANSMISSION;

ACUTE DISEASE; ANIMALS; ANTICONVULSANTS; BRAIN ISCHEMIA; CALCIUM CHANNELS; CELL MEMBRANE; EXTRACELLULAR SPACE; GLUTAMIC ACID; HUMANS; NEURAL INHIBITION; NEUROGLIA; NEUROPROTECTIVE AGENTS; POTASSIUM CHANNELS; PRESYNAPTIC TERMINALS; RECEPTORS, AMPA; RECEPTORS, CORTICOTROPIN; SEIZURES; SODIUM CHANNELS;

EID: 0038443830     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10603     Document Type: Review

References (80)

1. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37(suppl 6):S4-S11.
2. Moshe SI. Mechanisms of action of anticonvulsant agents. Neurology 2000;55(suppl 1):S32-S40.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
4. Lee J-M, Zipfel GJ, Choi DW. Changing landscape of ischaemic brain injury mechanisms. Nature 1999;399(suppl 24): A7-A14.
5. Calabresi P, Centonze D, Bernardi G. Cellular factors controlling neuronal vulnerability in the brain. A lesson from the striatum. Neurology 2000;55:1249-1255.
6. Plum F. Neuroprotection in acute ischemic stroke. JAMA 2001;13:1760-1761.
7. De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischemic stroke: are we doing the right thing? Trends Neurosci 1999;22:535-540.
8. Lees KR. Does neuroprotection improve stroke outcome? Lancet 1998;351:1447-1448.
9. Hainsworth AH, Stefani A, Calabresi P, et al. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Rev 2000;6:101-134.
10. Pulsinelli WA, Mann ME, Welch KMA, et al. Fosphenytoin in acute ischemic stroke: efficacy results. Neurology 1999;52(suppl 2):A384.
11. Davis SM, Alberts GW, Diener HC, et al. Termination of acute stroke studies involving selfotel treatment. Lancet 1997;349:32.
12. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995;26:254-258.
13. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(suppl 4):66-69.
14. Lees KR, Aspund K, Carolei A, et al., for the GAIN International Investigators. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised trial. Lancet 2000;355:1949-1954.
15. Sacco RL, DeRosa JT, Haley EC Jr, et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomised controlled trial. JAMA 2001;285:1719-1728.
16. Lyden P, Shuaib A, Ng K, et al. The CLASS-I/H/T Investigators. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke. 2002;33:122-128.
17. Siniscalchi A, Calabresi P, Mercuri NB, Bernardi G. Epileptiform discharge induced by 4-aminopyridine in magnesium-free medium in neocortical neurons: physiological and pharmacological characterization. Neuroscience 1997;81:189-197.
18. Calabresi P, Marfia GA, Centonze D, et al. Sodium influx plays a major role in the membrane depolarization induced by oxygen and glucose deprivation in rat striatal spiny neurons. Stroke 1999;30:171-179.
19. Centonze D, Marfia GA, Pisani A, et al. Ionic mechanisms underlying differential neuronal vulnerability in striatal neurons. Prog Neurobiol 2001;63:687-696.
20. Calabresi P, Centonze D, Pisani A, et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol 1998;43:586-597.
21. Murakami A, Furui T. Effects of the conventional anticonvulsants, phenytoin, carbamazepine, and valproic acid, on sodiumpotassium-adenosine triphosphatase in acute ischemic brain. Neurosurgery 1994;34:1047-1051.
22. Calabresi P, Centonze D, Marfia GA, et al. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br J Pharmacol 1999;126:689-696.
23. Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997;38:959-965.
24. Edmonds HL Jr, Jiang YD, Zhang PY, Shank R. Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration. Life Sci 2001;69:2265-2277.
25. Chan SA, Reid KH, Schurr A, et al. Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia. Acta Neurochir 1998;140:175-180.
26. Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm 1998;55:554-562.
27. Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998;804:169-176.
28. Calabresi P, Siniscalchi A, Pisani A, et al. A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology 1996;47:557-562.
29. Calabresi P, De Murtas M, Stefani A, et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 1995;36:990-996.
30. Catterall WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv Neurol 1999;79:441-456.
31. Leppik IE. Zonisamide. Epilepsia 1999;40(suppl 5):S23-S29.
32. Noda Y, Mori A, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res Commun Mol Pathol Pharmacol 1999;105:23-33.
33. Minato H, Kikuta C, Fujitani B, Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 1997;38:975-980.
34. Horn J, Limburg M. Calcium antagonists for ischemic stroke: a systematic review. Stroke 2001;32:570-576.
35. Calabresi P, Saulle E, Centonze D, et al. Post-ischaemic long-term synaptic potentiation in the striatum: a putative mechanism for cell type-specific vulnerability. Brain 2002;125:844-860.
36. Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke 1998;29:705-718.
37. Pisani A, Bonsi P, Centonze D, et al. Involvement of intracellular calcium stores during oxygen/glucose deprivation in striatal large aspiny interneurons. J Cereb Blood Flow Metab 2000;20:839-846.
38. Ghosh A, Greenberg ME. Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science 1995;268:239-247.
39. Wang SJ, Tsai JJ, Gean PW. Lamotrigine inhibits depolarization-evoked Ca++ influx in dissociated amygdala neurons. Synapse 1998;29:355-362.
40. Calabresi P, Picconi B, Saulle E, et al. Is pharmacological neuroprotection dependent on a reduced glutamate release? Stroke 2000;31:766-773.
41. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995;26:117-121.
42. Traystman RJ, Klaus JA, DeVries AC, et al. Anticonvulsant lamotrigine administered on reperfusion fails to improve experimental stroke outcomes. Stroke 2001;32:783-787.
43. Wiard RP, Dickerson MC, Beek O, et al. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke 1995;26:466-472.
44. Shuaib A, Mahmood RH, Wishart T, et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res 1995;702:199-206.
45. Crumrine RC, Bergstrand K, Cooper AT, et al. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 1997;28:2230-2236.
46. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18.
47. 2+ currents. Seizure 2001;10:279-286.
48. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001;10:287-293.
49. Morris GL. Gabapentin. Epilepsia 1999;40(suppl 5):S63-S70.
50. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-236.
51. Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998;37:83-91.
52. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001;2:241-271.
53. Pellock JM. Felbamate. Epilepsia 1999;40(suppl 5):S57-S62.
54. Pisani A, Stefani A, Siniscalchi A, et al. Electrophysiological actions of felbamate on rat striatal neurones. Br J Pharmacol 1995;116:2053-2061.
55. Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 2000;39:47-55.
56. Wasterlain CG, Adams LM, Schwartz PH, et al. Posthypoxic treatment with felbamate is neuroprotective in a rat model of hypoxia-ischemia. Neurology 1993;43:2303-2310.
57. Wasterlain CG, Adams LM, Wichmann JK, Sofia RD. Felbamate protects CA1 neurons from apoptosis in a gerbil model of global ischemia. Stroke 1996;27:1236-1240.
58. Shuaib A, Wagaar T, Ijaz MS, et al. Neuroprotection with felbamate: a 7- and 28-day study in transient forebrain ischemia in gerbils. Brain Res 1996;727:65-70.
59. Davies JA. Remacemide hydrochloryde: a novel antiepileptic agent. Gen Pharmacol 1997;28:499-502.
60. Arrowsmith JE, Harrison MJ, Newman SP, et al. Neuroprotection of the brain during cardiopulmonary bypass: a randomised trial of remacemide during coronary artery bypass in 171 patients. Stroke 1998;29:2357-2362.
61. Dyker AG, Lees KR. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke 1999;30:1796-1801.
62. Bannan PE, Graham DI, Lees KR, McCulloch J. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res 1994;664:271-275.
63. Palmer GC, Cregan EC, Borrelli AR, et al. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrocloride (FPL 13950) in animal models of hypoxia and global ischemia. J Pharmacol Exp Ther 1995;274:991-1000.
64. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 2001;42(suppl 3):8-12.
65. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischemic stroke. Neuropharmacology 2000;39:1438-1494.
66. Schwartz-Bloom RD, Sah R. Gamma-aminobutyric acid neurotransmission and cerebral ischemia. J Neurochem 2001;77:353-371.
67. Schwartz-Bloom RD, Miller KA, Evenson DA, et al. Benzodiazepines protect hippocampal neurons from degeneration after transient cerebral ischemia: an ultrastructural study. Neuroscience 2000;98:471-484.
68. Galeffi F, Sinnar S, Schwartz-Bloom RD. Diazepam promotes ATP recovery and prevents cytochrome c release in hippocampal slices after in vitro ischemia. J Neurochem 2000;75:1242-1249.
69. Snider BJ, Gottron FJ, Choi DW. Apoptosis and necrosis in cerebrovascular disease. Ann N Y Acad Sci 1999;893:243-253.
70. Lewis H, Wallace SJ. Vigabatrin. Dev Med Child Neurol 2001;43:833-835.
71. Genton P, Guerrini R, Perucca E. Tiagabine in clinical practice. Epilepsia 2001;42(suppl 3):42-45.
72. Chen Xu W, Yi Y, Qiu L, Shuaib A. Neuroprotective activity of tiagabine in a focal embolic model of cerebral ischemia. Brain Res 2000;874:75-77.
73. Yang Y, Li Q, Wang CX, et al. Dose-dependent neuroprotection with tiagabine in a focal cerebral ischemia model in rat. Neuroreport 2000;11:2307-2311.
74. Inglefield JR, Perry JM, Schwartz RD. Postischemic inhibition of GABA reuptake by tiagabine slows neuronal death in the gerbil hippocampus. Hippocampus 1995;5:460-468.
75. Shuaib A, Murabit MA, Kanthan R, et al. The neuroprotective effects of gamma-vinyl GABA in transient global ischemia: a morphological study with early and delayed evaluations. Neurosci Lett 1996;204:1-4.
76. Shuaib A, Ijaz S, Hasan S, Kalra J. Gamma-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia. Brain Res 1992;590:13-17.
77. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41:1364-1374.
78. Pisani F, Pedale S, Macaione V, et al. Neuroprotective effects of lamotrigine and remacemide on excitotoxicity induced by glutamate agonists in isolated chick retina. Exp Neurol 2001;170:162-170.
79. Calabresi P, Marti M, Picconi B, et al. Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. Exp Neurol (in press).
80. Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol 1999;45:421-429.